Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Aplan Website

Peter D. Aplan, M.D.

Selected Publications

1)  Aplan PD, Lombardi DP, Ginsberg AM, Cossman J, Bertness VL, Kirsch IR.
Disruption of the human SCL locus by.
Science. 250: 1426-9, 1990.
2)  Lin YW, Slape C, Zhang Z, Aplan PD.
NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.
Blood. 106: 287-95, 2005.
3)  Chung YJ, Choi CW, Slape C, Fry T, Aplan PD.
Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell.
Proc. Natl. Acad. Sci. U.S.A. 105: 14088-93, 2008.
4)  Gough SM, Lee F, Yang F, Walker RL, Zhu YJ, Pineda M, Onozawa M, Chung YJ, Bilke S, Wagner EK, Denu JM, Ning Y, Xu B, Wang GG, Meltzer PS, Aplan PD.
NUP98-PHF23 Is a Chromatin-Modifying Oncoprotein That Causes a Wide Array of Leukemias Sensitive to Inhibition of PHD Histone Reader Function.
Cancer Discov. 4: 564-77, 2014.
5)  Onozawa M, Zhang Z, Kim YJ, Goldberg L, Varga T, Bergsagel PL, Kuehl WM, Aplan PD.
Repair of DNA double-strand breaks by templated nucleotide sequence insertions derived from distant regions of the genome.
Proc. Natl. Acad. Sci. U.S.A. 111: 7729-34, 2014.
6)  Maegawa S, Gough SM, Watanabe-Okochi N, Lu Y, Zhang N, Castoro RJ, Estecio MR, Jelinek J, Liang S, Kitamura T, Aplan PD, Issa JP.
Age-related epigenetic drift in the pathogenesis of MDS and AML.
Genome Res. 24: 580-91, 2014.
7)  Bailey EJ, Duffield AS, Greenblatt SM, Aplan PD, Small D.
Effect of FLT3 ligand on survival and disease phenotype in murine models harboring a FLT3 internal tandem duplication mutation.
Comp. Med. 63: 218-26, 2013.
8)  Lacombe J, Krosl G, Tremblay M, Gerby B, Martin R, Aplan PD, Lemieux S, Hoang T.
Genetic interaction between Kit and Scl.
Blood. 122: 1150-61, 2013.
9)  Goldberg L, Tijssen MR, Birger Y, Hannah RL, Kinston SJ, Schütte J, Beck D, Knezevic K, Schiby G, Jacob-Hirsch J, Biran A, Kloog Y, Marcucci G, Bloomfield CD, Aplan PD, Pimanda JE, Göttgens B, Izraeli S.
Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.
Blood. 122: 2694-703, 2013.
10)  Beachy SH, Onozawa M, Silverman D, Chung YJ, Rivera MM, Aplan PD.
Isolated Hoxa9 overexpression predisposes to the development of lymphoid but not myeloid leukemia.
Exp. Hematol. 41: 518-529, 2013.
Click Here to View Expanded Bibliography.

This page was last updated on 6/16/2014.